How to buy Urovant Sciences stock

Urovant Sciences Ltd is a biotechnology business based in the US. Urovant Sciences shares (UROV) are listed on the NASDAQ and all prices are listed in US Dollars. Urovant Sciences employs 70 staff and has a market cap (total outstanding shares value) of 0.00.

Urovant Sciences share price

Use our graph to track the performance of UROV stocks over time.

Urovant Sciences shares at a glance

• Key figures

Information last updated 2021-04-27.

52-week range	$7.15 - $16.26
50-day moving average	$16.21
200-day moving average	$13.98
Wall St. target price	$16.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.92

Buy Urovant Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Urovant Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Urovant Sciences Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Urovant Sciences financials

Gross profit TTM	$0
Return on assets TTM	-75.13%
Return on equity TTM	0%
Profit margin	0%
Book value	$0.78
Market capitalisation	$531.8 million

TTM: trailing 12 months

Shorting Urovant Sciences shares

There are currently 130,651 Urovant Sciences shares held short by investors – that's known as Urovant Sciences's "short interest". This figure is 67.3% up from 78,104 last month.

There are a few different ways that this level of interest in shorting Urovant Sciences shares can be evaluated.

Urovant Sciences's "short interest ratio" (SIR)

Urovant Sciences's "short interest ratio" (SIR) is the quantity of Urovant Sciences shares currently shorted divided by the average quantity of Urovant Sciences shares traded daily (recently around 59657.99086758). Urovant Sciences's SIR currently stands at 2.19. In other words for every 100,000 Urovant Sciences shares traded daily on the market, roughly 2190 shares are currently held short.

However Urovant Sciences's short interest can also be evaluated against the total number of Urovant Sciences shares, or, against the total number of tradable Urovant Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Urovant Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Urovant Sciences shares in existence, roughly 0 shares are currently held short) or 0.0134% of the tradable shares (for every 100,000 tradable Urovant Sciences shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Urovant Sciences.

Find out more about how you can short Urovant Sciences stock.

Urovant Sciences share dividends

We're not expecting Urovant Sciences to pay a dividend over the next 12 months.

Urovant Sciences share price volatility

Over the last 12 months, Urovant Sciences's shares have ranged in value from as little as $7.15 up to $16.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Urovant Sciences's is 2.3354. This would suggest that Urovant Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Urovant Sciences overview

Urovant Sciences Ltd. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017.

Frequently asked questions

• What percentage of Urovant Sciences is owned by insiders or institutions?

  Currently 71.346% of Urovant Sciences shares are held by insiders and 19.213% by institutions.

• How many people work for Urovant Sciences?

  Latest data suggests 70 work at Urovant Sciences.

• When does the fiscal year end for Urovant Sciences?

  Urovant Sciences's fiscal year ends in March.

• Where is Urovant Sciences based?

  Urovant Sciences's address is: 11-12 Street, James?s Square, London, United Kingdom, SW1Y 4LB

• What is Urovant Sciences's ISIN number?

  Urovant Sciences's international securities identification number is: BMG9381B1081

• What is Urovant Sciences's CUSIP number?

  Urovant Sciences's Committee on Uniform Securities Identification Procedures number is: G9381B108